NewLink Genetics Corporation (NLNK) : The consensus on NewLink Genetics Corporation (NLNK) based on 6 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
NewLink Genetics Corporation (NLNK) : The most positive equity analysts on NewLink Genetics Corporation (NLNK) expects the shares to touch $23, whereas, the least positive believes that the stock will trade at $10 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $17.83 with an expected fluctuation of $5.46 from the mean.
NewLink Genetics Corporation has lost 2.56% in the last five trading days and dropped 8.15% in the last 4 weeks. NewLink Genetics Corporation has dropped 4.29% during the last 3-month period . Year-to-Date the stock performance stands at -71.81%. NewLink Genetics Corporation (NASDAQ:NLNK): On Tuesdays trading session , Opening price of the stock was $10.39 with an intraday high of $10.4499. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $10.0306. However, the stock managed to close at $10.26, a loss of 0.58% for the day. On the previous day, the stock had closed at $10.32. The total traded volume of the day was 166,186 shares.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune systems tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.